We are analyzing https://link.springer.com/article/10.1007/s10147-017-1231-x.

Title:
Incidence, risk and prognostic role of anti-epidermal growth factor receptor-induced skin rash in biliary cancer: a meta-analysis | International Journal of Clinical Oncology
Description:
Anti-epidermal growth factor receptor (EGFR)-induced skin rash is a common adverse event and is considered a prognostic factor of various cancers. However, the role of rash is rarely known in biliary cancer, possibly owing to the low incidence of this frequently fatal malignancy. We thus performed a meta-analysis to investigate the incidence, risk and prognostic significance of skin rash related to anti-EGFR treatment for biliary cancer. Eligible studies were enrolled after a systematic search of electronic databases. A fixed-effects or random-effects model was utilized according to the heterogeneity. Fourteen clinical trials published between 2006 and 2017 comprising 1,106 patients with advanced biliary cancer were included. The overall incidence of all-grade and high-grade (grade ≥3) rash was 78.2% [95% confidence interval (CI) 70.4–84.3] and 11.3% (7.6–16.5), respectively. Anti-EGFR treatment correlates with a significantly increased risk of all-grade [risk ratio (RR) 7.37, 95% CI 5.11–10.64, p < 0.0001] and high-grade (RR 6.94, 95% CI 1.89–25.45, p = 0.0035) rash compared with control medication. Higher grades of skin rash correlate with a higher objective response rate (RR 3.50, 95% CI 1.47–8.33, p = 0.0048), and a longer overall [hazard ratio (HR) 0.47, 95% CI 0.31–0.71, p = 0.0003) and progression-free survival (HR 0.51, 95% CI 0.36–0.72, p = 0.0001) compared with lower grades or no rash in patients who received anti-EGFR treatment. Anti-EGFR treatment correlates with an increased risk of skin rash in advanced biliary cancer. Stratifying patients by the severity of rash may have major implications for survival benefit regarding anti-EGFR treatment for biliary cancer.
Website Age:
28 years and 1 months (reg. 1997-05-29).

Matching Content Categories {📚}

Education
Health & Fitness
Science

Content Management System {📝}

What CMS is link.springer.com built with?

Custom-built

No common CMS systems were detected on Link.springer.com, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of link.springer.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month

Based on our best estimate, this website will receive around 5,000,019 visitors per month in the current month.
However, some sources were not loaded, we suggest to reload the page to get complete results.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Link.springer.com Make Money? {💸}

We're unsure how the site profits.

While many websites aim to make money, others are created to share knowledge or showcase creativity. People build websites for various reasons. This could be one of them. Link.springer.com might be making money, but it's not detectable how they're doing it.

Keywords {🔍}

article, pubmed, cancer, google, scholar, cas, oncol, biliary, phase, patients, rash, advanced, skin, gemcitabine, tract, clin, trial, study, cetuximab, factor, metaanalysis, treatment, growth, receptor, antiegfr, systematic, panitumumab, risk, med, oxaliplatin, erlotinib, clinical, review, trials, metastatic, colorectal, tyrosine, kinase, inhibitors, cell, lung, engl, lancet, combination, central, privacy, cookies, content, data, journal,

Topics {✒️}

kras wild-type unresectable month download article/chapter small-cell lung cancer advanced biliary-tract cancer anti-egfr treatment correlates received anti-egfr treatment randomized double-blind trial cetuximab-induced skin rash common adverse event receptor tyrosine kinases open-label single-arm metastatic biliary tract biliary tract cancer induced skin rash literature-based meta-analysis metastatic colorectal cancer skin rash related skin toxicity induced article international journal anti-egfr treatment advanced biliary cancer full article pdf unresectable biliary cancer anti-inflammatory activity phase ii trial biliary tract cancers skin rash correlate early skin rash risk factor analysis prophylactic oral minocycline privacy choices/manage cookies phase iii trial phase ii study related subjects colorectal liver metastases advanced pancreatic cancer colorectal cancer patients progression-free survival china scholarship council cetuximab-induced rash article wei egfr signaling pathway kinase inhibitors cancer patients treated anti-egfr national cancer institute clinical oncology aims biliary cancer vecti-bil study european economic area

Schema {🗺️}

WebPage:
      mainEntity:
         headline:Incidence, risk and prognostic role of anti-epidermal growth factor receptor-induced skin rash in biliary cancer: a meta-analysis
         description:Anti-epidermal growth factor receptor (EGFR)-induced skin rash is a common adverse event and is considered a prognostic factor of various cancers. However, the role of rash is rarely known in biliary cancer, possibly owing to the low incidence of this frequently fatal malignancy. We thus performed a meta-analysis to investigate the incidence, risk and prognostic significance of skin rash related to anti-EGFR treatment for biliary cancer. Eligible studies were enrolled after a systematic search of electronic databases. A fixed-effects or random-effects model was utilized according to the heterogeneity. Fourteen clinical trials published between 2006 and 2017 comprising 1,106 patients with advanced biliary cancer were included. The overall incidence of all-grade and high-grade (grade ≥3) rash was 78.2% [95% confidence interval (CI) 70.4–84.3] and 11.3% (7.6–16.5), respectively. Anti-EGFR treatment correlates with a significantly increased risk of all-grade [risk ratio (RR) 7.37, 95% CI 5.11–10.64, p < 0.0001] and high-grade (RR 6.94, 95% CI 1.89–25.45, p = 0.0035) rash compared with control medication. Higher grades of skin rash correlate with a higher objective response rate (RR 3.50, 95% CI 1.47–8.33, p = 0.0048), and a longer overall [hazard ratio (HR) 0.47, 95% CI 0.31–0.71, p = 0.0003) and progression-free survival (HR 0.51, 95% CI 0.36–0.72, p = 0.0001) compared with lower grades or no rash in patients who received anti-EGFR treatment. Anti-EGFR treatment correlates with an increased risk of skin rash in advanced biliary cancer. Stratifying patients by the severity of rash may have major implications for survival benefit regarding anti-EGFR treatment for biliary cancer.
         datePublished:2017-12-30T00:00:00Z
         dateModified:2017-12-30T00:00:00Z
         pageStart:443
         pageEnd:451
         sameAs:https://doi.org/10.1007/s10147-017-1231-x
         keywords:
            Skin rash
            Anti-EGFR
            Biliary cancer
            Survival
            Meta-analysis
            Oncology
            Surgical Oncology
            Cancer Research
         image:
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10147-017-1231-x/MediaObjects/10147_2017_1231_Fig1_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10147-017-1231-x/MediaObjects/10147_2017_1231_Fig2_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10147-017-1231-x/MediaObjects/10147_2017_1231_Fig3_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10147-017-1231-x/MediaObjects/10147_2017_1231_Fig4_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10147-017-1231-x/MediaObjects/10147_2017_1231_Fig5_HTML.gif
         isPartOf:
            name:International Journal of Clinical Oncology
            issn:
               1437-7772
               1341-9625
            volumeNumber:23
            type:
               Periodical
               PublicationVolume
         publisher:
            name:Springer Japan
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Fangqiang Wei
               affiliation:
                     name:Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University
                     address:
                        name:Department of General Surgery, Institute of Minimally Invasive Surgery, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, China
                        type:PostalAddress
                     type:Organization
                     name:Pittsburgh Liver Research Center, McGowan Institute for Regenerative Medicine, School of Medicine, University of Pittsburgh
                     address:
                        name:Department of Developmental Biology, Pittsburgh Liver Research Center, McGowan Institute for Regenerative Medicine, School of Medicine, University of Pittsburgh, Pittsburgh, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Donghun Shin
               affiliation:
                     name:Pittsburgh Liver Research Center, McGowan Institute for Regenerative Medicine, School of Medicine, University of Pittsburgh
                     address:
                        name:Department of Developmental Biology, Pittsburgh Liver Research Center, McGowan Institute for Regenerative Medicine, School of Medicine, University of Pittsburgh, Pittsburgh, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Xiujun Cai
               url:http://orcid.org/0000-0003-2514-1486
               affiliation:
                     name:Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University
                     address:
                        name:Department of General Surgery, Institute of Minimally Invasive Surgery, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, China
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
         isAccessibleForFree:
         hasPart:
            isAccessibleForFree:
            cssSelector:.main-content
            type:WebPageElement
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:Incidence, risk and prognostic role of anti-epidermal growth factor receptor-induced skin rash in biliary cancer: a meta-analysis
      description:Anti-epidermal growth factor receptor (EGFR)-induced skin rash is a common adverse event and is considered a prognostic factor of various cancers. However, the role of rash is rarely known in biliary cancer, possibly owing to the low incidence of this frequently fatal malignancy. We thus performed a meta-analysis to investigate the incidence, risk and prognostic significance of skin rash related to anti-EGFR treatment for biliary cancer. Eligible studies were enrolled after a systematic search of electronic databases. A fixed-effects or random-effects model was utilized according to the heterogeneity. Fourteen clinical trials published between 2006 and 2017 comprising 1,106 patients with advanced biliary cancer were included. The overall incidence of all-grade and high-grade (grade ≥3) rash was 78.2% [95% confidence interval (CI) 70.4–84.3] and 11.3% (7.6–16.5), respectively. Anti-EGFR treatment correlates with a significantly increased risk of all-grade [risk ratio (RR) 7.37, 95% CI 5.11–10.64, p < 0.0001] and high-grade (RR 6.94, 95% CI 1.89–25.45, p = 0.0035) rash compared with control medication. Higher grades of skin rash correlate with a higher objective response rate (RR 3.50, 95% CI 1.47–8.33, p = 0.0048), and a longer overall [hazard ratio (HR) 0.47, 95% CI 0.31–0.71, p = 0.0003) and progression-free survival (HR 0.51, 95% CI 0.36–0.72, p = 0.0001) compared with lower grades or no rash in patients who received anti-EGFR treatment. Anti-EGFR treatment correlates with an increased risk of skin rash in advanced biliary cancer. Stratifying patients by the severity of rash may have major implications for survival benefit regarding anti-EGFR treatment for biliary cancer.
      datePublished:2017-12-30T00:00:00Z
      dateModified:2017-12-30T00:00:00Z
      pageStart:443
      pageEnd:451
      sameAs:https://doi.org/10.1007/s10147-017-1231-x
      keywords:
         Skin rash
         Anti-EGFR
         Biliary cancer
         Survival
         Meta-analysis
         Oncology
         Surgical Oncology
         Cancer Research
      image:
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10147-017-1231-x/MediaObjects/10147_2017_1231_Fig1_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10147-017-1231-x/MediaObjects/10147_2017_1231_Fig2_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10147-017-1231-x/MediaObjects/10147_2017_1231_Fig3_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10147-017-1231-x/MediaObjects/10147_2017_1231_Fig4_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10147-017-1231-x/MediaObjects/10147_2017_1231_Fig5_HTML.gif
      isPartOf:
         name:International Journal of Clinical Oncology
         issn:
            1437-7772
            1341-9625
         volumeNumber:23
         type:
            Periodical
            PublicationVolume
      publisher:
         name:Springer Japan
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Fangqiang Wei
            affiliation:
                  name:Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University
                  address:
                     name:Department of General Surgery, Institute of Minimally Invasive Surgery, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, China
                     type:PostalAddress
                  type:Organization
                  name:Pittsburgh Liver Research Center, McGowan Institute for Regenerative Medicine, School of Medicine, University of Pittsburgh
                  address:
                     name:Department of Developmental Biology, Pittsburgh Liver Research Center, McGowan Institute for Regenerative Medicine, School of Medicine, University of Pittsburgh, Pittsburgh, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Donghun Shin
            affiliation:
                  name:Pittsburgh Liver Research Center, McGowan Institute for Regenerative Medicine, School of Medicine, University of Pittsburgh
                  address:
                     name:Department of Developmental Biology, Pittsburgh Liver Research Center, McGowan Institute for Regenerative Medicine, School of Medicine, University of Pittsburgh, Pittsburgh, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Xiujun Cai
            url:http://orcid.org/0000-0003-2514-1486
            affiliation:
                  name:Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University
                  address:
                     name:Department of General Surgery, Institute of Minimally Invasive Surgery, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, China
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
      isAccessibleForFree:
      hasPart:
         isAccessibleForFree:
         cssSelector:.main-content
         type:WebPageElement
["Periodical","PublicationVolume"]:
      name:International Journal of Clinical Oncology
      issn:
         1437-7772
         1341-9625
      volumeNumber:23
Organization:
      name:Springer Japan
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University
      address:
         name:Department of General Surgery, Institute of Minimally Invasive Surgery, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, China
         type:PostalAddress
      name:Pittsburgh Liver Research Center, McGowan Institute for Regenerative Medicine, School of Medicine, University of Pittsburgh
      address:
         name:Department of Developmental Biology, Pittsburgh Liver Research Center, McGowan Institute for Regenerative Medicine, School of Medicine, University of Pittsburgh, Pittsburgh, USA
         type:PostalAddress
      name:Pittsburgh Liver Research Center, McGowan Institute for Regenerative Medicine, School of Medicine, University of Pittsburgh
      address:
         name:Department of Developmental Biology, Pittsburgh Liver Research Center, McGowan Institute for Regenerative Medicine, School of Medicine, University of Pittsburgh, Pittsburgh, USA
         type:PostalAddress
      name:Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University
      address:
         name:Department of General Surgery, Institute of Minimally Invasive Surgery, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, China
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Fangqiang Wei
      affiliation:
            name:Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University
            address:
               name:Department of General Surgery, Institute of Minimally Invasive Surgery, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, China
               type:PostalAddress
            type:Organization
            name:Pittsburgh Liver Research Center, McGowan Institute for Regenerative Medicine, School of Medicine, University of Pittsburgh
            address:
               name:Department of Developmental Biology, Pittsburgh Liver Research Center, McGowan Institute for Regenerative Medicine, School of Medicine, University of Pittsburgh, Pittsburgh, USA
               type:PostalAddress
            type:Organization
      name:Donghun Shin
      affiliation:
            name:Pittsburgh Liver Research Center, McGowan Institute for Regenerative Medicine, School of Medicine, University of Pittsburgh
            address:
               name:Department of Developmental Biology, Pittsburgh Liver Research Center, McGowan Institute for Regenerative Medicine, School of Medicine, University of Pittsburgh, Pittsburgh, USA
               type:PostalAddress
            type:Organization
      name:Xiujun Cai
      url:http://orcid.org/0000-0003-2514-1486
      affiliation:
            name:Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University
            address:
               name:Department of General Surgery, Institute of Minimally Invasive Surgery, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, China
               type:PostalAddress
            type:Organization
      email:[email protected]
PostalAddress:
      name:Department of General Surgery, Institute of Minimally Invasive Surgery, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, China
      name:Department of Developmental Biology, Pittsburgh Liver Research Center, McGowan Institute for Regenerative Medicine, School of Medicine, University of Pittsburgh, Pittsburgh, USA
      name:Department of Developmental Biology, Pittsburgh Liver Research Center, McGowan Institute for Regenerative Medicine, School of Medicine, University of Pittsburgh, Pittsburgh, USA
      name:Department of General Surgery, Institute of Minimally Invasive Surgery, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, China
WebPageElement:
      isAccessibleForFree:
      cssSelector:.main-content

External Links {🔗}(192)

Analytics and Tracking {📊}

Google Tag Manager

Libraries {📚}

Clipboard.js
Prism.js

CDN Services {📦}

Crossref

4.07s.

LINK . SPRINGER . COM {}